Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma

Abstract

Talimogene laherparepvec (T-VEC) is an oncolytic virus (OV) therapy derived from the JS1 strain of herpes simplex virus one that was approved by the Food and Drug Administration in 2015 to be administered as direct injection therapy for patients with melanoma. The anti-tumor effects of T-VEC are due to viral-mediated tumor cell lysis at the site of administration and a local, and in some cases systemic, anti-tumor response via T cell-mediated host immune response pathways aided by GM-CSF. T-VEC has shown promising results for metastatic melanoma, particularly in patients with skin, lymph node, and soft tissue metastases (stages IIIB, IIIC, and IVa). Studies have explored the utility of T-VEC as monotherapy, neoadjuvant therapy, and in combination with other immunotherapies and targeted therapies. T-VEC has proven to improve durable response rates and overall survival with a very tolerable safety profile. More research is needed to better understand which patients are most likely to benefit from T-VEC therapy, which combination therapies are most effective, and how to sequence multimodality therapy. Additionally, new OVs are currently in development and/or being studied in clinical trials. In this review, we will discuss T-VEC as a monotherapy, neoadjuvant therapy, and combination therapy, in addition to future directions for melanoma therapy as it pertains to new OVs.

Keywords

Talimogene laherparepvec / melanoma / immunotherapy / intralesional therapy / oncolytic virus / neoadjuvant therapy

References

[1] Berk-KraussJ,WeberJ,GellerAC.New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986-2016.Am J Public Health2020;110:731-3 PMCID:PMC7144422

[2] National Cancer Institute. Drugs approved for melanoma. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/melanoma [Last accessed on 16 Aug 2021]

[3] LouieRJ,JajjaMR.Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience.J Am Coll Surg2019;228:644-9

[4] PointerDT Jr.Management of locoregionally advanced melanoma.Surg Clin North Am2020;100:109-25

[5] SongX,BarberB,IvanovB.Overall survival in patients with metastatic melanoma.Curr Med Res Opin2015;31:987-91

[6] National Cancer Institute. SEER cancer stat facts: melanoma of the skin. Available from: https://seer.cancer.gov/statfacts/html/melan.html [Last accessed on 16 Aug 2021]

[7] National Cancer Institute. Melanoma of the skin: recent trends in SEER relative survival rates, 2000-2018. Available from: https://seer.cancer.gov/explorer/application.html [Last accessed on 16 Aug 2021]

[8] National Comprehensive Cancer Network. Melanoma: cutaneous (Version 2.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf [Last accessed on 16 Aug 2021]

[9] AndtbackaRH,CollichioF.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol2015;33:2780-8

[10] RibasA,PuzanovI.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy.Cell2018;174:1031-2

[11] BommareddyPK,ZlozaA,KaufmanHL.MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.Sci Transl Med2018;10:eaau0417 PMCID:PMC7593827

[12] ConryRM,McKeeS.Talimogene laherparepvec: First in class oncolytic virotherapy.Hum Vaccin Immunother2018;14:839-46 PMCID:PMC5893211

[13] KohlhappFJ.Molecular Pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy.Clin Cancer Res2016;22:1048-54

[14] LiuBL,HanZQ.ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.Gene Ther2003;10:292-303

[15] MohrI,WardS,MulveyM.A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.J Virol2001;75:5189-96 PMCID:PMC114924

[16] TanejaS,MarkusS,MohrI.Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.Proc Natl Acad Sci U S A2001;98:8804-8 PMCID:PMC37516

[17] TodoT,RabkinSD.Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.Proc Natl Acad Sci U S A2001;98:6396-401 PMCID:PMC33479

[18] HeB,BrandimartiR,GluzmanY.Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene.J Virol1997;71:6049-54 PMCID:PMC191863

[19] MohrI.A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.Embo j1996;15:4759-66 PMCID:PMC452208

[20] CassadyKA,RoizmanB.The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2.J Virol1998;72:8620-6 PMCID:PMC110273

[21] TodaM,RabkinSD.Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.Mol Ther2000;2:324-9

[22] KaufmanHL,DeRaffeleG,CoffinRS.Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Ann Surg Oncol2010;17:718-30

[23] HuJC,DavisCJ.A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.Clin Cancer Res2006;12:6737-47

[24] HarringtonKJ,TanayMA.Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.Clin Cancer Res2010;16:4005-15

[25] SenzerNN,AmatrudaT.Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.J Clin Oncol2009;27:5763-71

[26] AndtbackaRHI,NemunaitisJ.Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.EBioMedicine2019;47:89-97 PMCID:PMC6796514

[27] CollichioF,ProctorA.Implementing a program of talimogene laherparepvec.Ann Surg Oncol2018;25:1828-35

[28] BurkeLMB,BurkeK.Ultrasound-guided intralesional injection of talimogene laherparepvec (imlygic) for advanced melanoma: technical note on a preliminary experience.Cardiovasc Intervent Radiol2021;44:801-6

[29] AndtbackaRHI,HarringtonKJ.Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.J Immunother Cancer2019;7:145 PMCID:PMC6554874

[30] AndtbackaRH,PuzanovI.Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial.Ann Surg Oncol2016;23:4169-77 PMCID:PMC5090012

[31] U.S. Food and Drug Administration. IMLYGIC (talimogene laherparepvec). Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec [Last accessed on 16 Aug 2021]

[32] U.S. National Institutes of Health. Postmarketing prospective study of melanoma patients treated with IMLYGIC® to characterize risk of herpetic infection. Available from: https://clinicaltrials.gov/ct2/show/NCT02910557 [Last accessed on 16 Aug 2021]

[33] Health USNIo. A registry study to evaluate the survival and long-term safety of subjects who previously received talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trials. Available from: https://clinicaltrials.gov/ct2/show/NCT02173171 [Last accessed on 16 Aug 2021]

[34] PuzanovI,MinorD.Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma.J Clin Oncol2016;34:2619-26 PMCID:PMC7189507

[35] ChesneyJ,CollichioF.Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.J Clin Oncol2018;36:1658-67 PMCID:PMC6075852

[36] PuzanovI,CollichioF.433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial.J Immunother Cancer2020;8:A459-A459

[37] ChesneyJ,CollichioF.Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.Br J Cancer2019;121:417-20 PMCID:PMC6738060

[38] MoestaAK,PiaseckiJ.Local delivery of OncoVEX^mGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade.Clin Cancer Res2017;23:6190-202

[39] LongG,JohnsonD.429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma.J Immunother Cancer2020;8:A454

[40] U.S. National Institutes of Health. Pembrolizumab with or without talimogene laherparepvec or talimogene laherparepvec placebo in unresected melanoma (KEYNOTE-034). Available from: https://clinicaltrials.gov/ct2/show/NCT02263508 [Last accessed on 16 Aug 2021]

[41] U.S. National Institutes of Health. Talimogene laherparepvec and pembrolizumab in treating patients with stage III-IV melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02965716 [Last accessed on 16 Aug 2021]

[42] U.S. National Institutes of Health. Talimogene laherparepvec with pembrolizumab in melanoma following progression on prior Anti-PD-1 based therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). Available from: https://clinicaltrials.gov/ct2/show/NCT04068181 [Last accessed on 16 Aug 2021]

[43] U.S. National Institutes of Health. Trial to evaluate the safety of talimogene laherparepvec injected into tumors alone and in combination with systemic pembrolizumab MK-3475-611/Keynote-611 (MASTERKEY-318). Available from: https://clinicaltrials.gov/ct2/show/NCT02509507 [Last accessed on 16 Aug 2021]

[44] SunL,SongJM.Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.J Immunother Cancer2018;6:36 PMCID:PMC5954455

[45] BeheraTR,KoJS,FunchainP.Real-world experience of talimogene laherparepvec in patients receiving immunotherapy in metastatic melanoma.J Clin Oncol2020;38:e22003

[46] LongGV,GogasH.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med2014;371:1877-88

[47] KakadiaS,AwadR.Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.Onco Targets Ther2018;11:7095-107 PMCID:PMC6200076

[48] GholamiS,GaoS.Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.Cancer Gene Ther2014;21:283-9

[49] U.S. National Institutes of Health. Combining talimogene laherparepvec with BRAF and MEK inhibitors in BRAF mutated advanced melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT03088176 [Last accessed on 16 Aug 2021]

[50] U.S. National Institutes of Health. Intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) (myDCTV). Available from: https://clinicaltrials.gov/ct2/show/NCT03747744 [Last accessed on 16 Aug 2021]

[51] BrozML,BoldajipourB.Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.Cancer Cell2014;26:638-52 PMCID:PMC4254577

[52] RobertsEW,BinnewiesM.Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of t cell immunity in melanoma.Cancer Cell2016;30:324-36 PMCID:PMC5374862

[53] U.S. National Institutes of Health. TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (TITAN). Available from: https://clinicaltrials.gov/ct2/show/NCT03555032 [Last accessed on 16 Aug 2021]

[54] U.S. National Institutes of Health. A Study of T-VEC (Talimogene Laherparepvec) With or without radiotherapy for melanoma, merkel cell carcinoma, or other solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02819843 [Last accessed on 16 Aug 2021]

[55] KellyZR,DavarD.The role of neoadjuvant therapy in melanoma.Curr Oncol Rep2020;22:80

[56] PelsterMS.Neoadjuvant Immunotherapy for Locally Advanced Melanoma.Curr Treat Options Oncol2020;21:10

[57] U.S. National Institutes of Health. Neoadjuvant T-VEC in high risk early melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT04427306 [Last accessed on 16 Aug 2021]

[58] U.S. National Institutes of Health. Efficacy and safety of talimogene laherparepvec neoadjuvant treatment plus surgery versus surgery alone for melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02211131 [Last accessed on 16 Aug 2021]

[59] AndtbackaRHI,GyorkiDE.Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).J Clin Oncol2018;36:9508

[60] DummerR,HyngstromJR.One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).J Clin Oncol2019;37:9520

[61] DummerR,HyngstromJ.Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma.Ann Oncol2019;30:v903

[62] DummerR,HyngstromJ.432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma.J Immunother Cancer2020;8:A458

[63] U.S. National Institutes of Health. Neo-adjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (Stage IIIB/C/D-IV M1a) melanoma with injectable disease (NIVEC). Available from: https://clinicaltrials.gov/ct2/show/NCT04330430 [Last accessed on 16 Aug 2021]

[64] U.S. National Institutes of Health. Neoadjuvant combination immunotherapy for stage III melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT03842943 [Last accessed on 16 Aug 2021]

[65] U.S. National Institutes of Health. Ipilimumab with or without talimogene laherparepvec in unresected melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01740297 [Last accessed on 16 Aug 2021]

[66] BradleyS,HarringtonK,MelcherA.Applications of coxsackievirus A21 in oncology.Oncolytic Virother2014;3:47-55 PMCID:PMC4918364

[67] HamidO,PuzanovI.Intratumoral immunotherapy-update 2019.Oncologist2020;25:e423-38 PMCID:PMC7066689

[68] EissaIR,IchinoseT.The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers.Cancers (Basel)2018;10:356 PMCID:PMC6210336

[69] U.S. National Institutes of Health. A clinical trial assessing BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT04725331 [Last accessed on 16 Aug 2021]

[70] HavunenR,SiuralaM.Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor Anti-PD-1.Cells2021;10:246 PMCID:PMC7911972

[71] U.S. National Institutes of Health. A pilot study of sequential ONCOS-102, an engineered oncolytic adenovirus expressing GMCSF, and pembrolizumab in patients with advanced or unresectable melanoma progressing after programmed cell death protein 1 (PD1) blockade. Available from: https://clinicaltrials.gov/ct2/show/NCT03003676 [Last accessed on 16 Aug 2021]

[72] KurykL,JaderbergM.Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.Oncoimmunology2019;8:e1532763 PMCID:PMC6343802

[73] KyoS,FujiwaraT.Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.Cancer Sci2008;99:1528-38

[74] U.S. National Institutes of Health. Evaluate efficacy, immunological response of intratumoral/intralesional oncolytic virus (OBP-301) in metastatic melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT03190824 [Last accessed on 16 Aug 2021]

[75] EissaIR,Bustos-VillalobosI.Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials.Front Oncol2017;7:149 PMCID:PMC5509757

[76] HainesBB,GrzesikP.ONCR-177, an Oncolytic HSV-1 designed to potently activate systemic antitumor immunity.Cancer Immunol Res2021;9:291-308

[77] ThomasS,RoulstoneV.Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.J Immunother Cancer2019;7:214 PMCID:PMC6689178

[78] MiddletonMR,SaccoJ.An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: initial results from the skin cancer cohorts.J Clin Oncol2020;38:e22050

[79] U.S. National Institutes of Health. OH2 Injection in Combination With HX008 for Melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT04616443 [Last accessed on 16 Aug 2021]

[80] ZhaoQ,NingZ.A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.PLoS One2014;9:e93103 PMCID:PMC3966855